Product image of Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic) supplied by GNH India

Influvac

Active Ingredient:
Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic
Origin:
EU

Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

influenza virus vaccine, the active ingredient in Influvac, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It prevents influenza infection caused by influenza A and B viruses in individuals at risk.

GNH India supplies Influvac as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Healthcare Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Influvac is a vaccine that targets the influenza virus family to provide active immunization against seasonal flu.

  • Seasonal influenza (influenza A and B): provides active immunization to reduce the incidence of flu illness.
  • High‑risk populations (elderly, chronic disease patients): lowers the risk of severe influenza complications.
  • Community health programs: contributes to herd immunity and reduces overall flu transmission.

How It Works

  • Influvac contains purified hemagglutinin and neuraminidase antigens from the selected influenza A and B strains. After intramuscular or subcutaneous injection, these antigens are recognized by the immune system, prompting B‑cell activation and the production of strain‑specific antibodies, thereby establishing active immunity against future exposure to the virus.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Low‑grade fever: transient temperature rise.
  • Headache: mild headache within 24 hours.
  • Myalgia: muscle aches.
  • Fatigue: temporary tiredness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical care.
  • Guillain‑Barré syndrome: rare neurological disorder.
  • Severe allergic reaction: urticaria, angioedema, or respiratory distress.
  • High fever: temperature >39 °C persisting beyond 48 hours.
  • Seizures: uncommon neurologic event.
  • Myocarditis: rare inflammation of heart muscle.

Precautions & Warnings

Before administration, consider the following precautions:

  • Severe allergy: avoid if the patient has a known hypersensitivity to any vaccine component.
  • Acute illness: postpone vaccination in individuals with moderate or severe febrile illness.
  • Prior Guillain‑Barré syndrome: evaluate risk‑benefit before use.
  • Pregnancy and lactation: administer only if potential benefits outweigh theoretical risks.
  • Immunocompromised patients: vaccine may be less effective; monitor response.
  • Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vaccines can interact with other agents that affect immune response.

Major Interactions (Avoid)

  • Immunoglobulin therapy: may diminish vaccine‑induced immunity.
  • Live viral vaccines: avoid simultaneous administration due to potential interference.

Moderate Interactions (Monitor Closely)

  • Antipyretics (acetaminophen, ibuprofen): prophylactic use may reduce antibody response.
  • Immunosuppressive therapy: may lower vaccine efficacy.
  • Corticosteroids: may affect immune response to the vaccine.

Frequently Asked Questions

Influvac is a seasonal influenza vaccine indicated for active immunization against influenza A and B viruses, helping to prevent flu illness in both adults and children when administered according to public health guidelines.

The vaccine contains purified viral antigens that stimulate the immune system to produce antibodies against hemagglutinin and neuraminidase proteins, establishing active immunity that can neutralize the influenza virus upon future exposure.

The prescribed dose is determined by the treating healthcare professional based on the patient’s age, health status, and local immunization recommendations, and is delivered as a single intramuscular or subcutaneous injection.

Safety data are limited; the vaccine may be administered during pregnancy or lactation only when the potential benefits to the mother and fetus outweigh any theoretical risks, and the decision should be made by a qualified clinician.

Submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Influvac contains the WHO‑recommended strains similar to other licensed quadrivalent or trivalent vaccines. Formulation differences such as split‑virus versus subunit may affect reactogenicity, but overall efficacy is comparable when administered according to recommended schedules.

Store the vaccine at 2‑8 °C in a refrigerator, protect it from light, and never freeze or shake the vial. Keep it in the original packaging until use to maintain potency and stability.

A qualified healthcare professional injects Influvac intramuscularly, typically into the deltoid muscle, or subcutaneously if indicated, using a sterile needle and syringe following standard aseptic technique.

Rare but serious adverse events include anaphylaxis, severe allergic reactions, and Guillain‑Barré syndrome. Patients should be observed after vaccination and seek immediate medical attention if they experience breathing difficulty, swelling, or neurological changes.

Individuals with a known severe allergy to any vaccine component, those who have experienced a previous severe reaction to an influenza vaccine, or persons with a history of Guillain‑Barré syndrome following a prior influenza vaccination should avoid Influvac unless specifically advised by a clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT